BOSTON, Sept. 24, 2025) ("Tiziana" or the "Company"), a biotechnology company developing breakthrough immunomodulation therapies with its lead development candidate, intranasal foralumab, a fully ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback